Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

BridgeBio Pharma, Inc.

NASDAQ: BBIO · Life Sciences · 6 alerts · CIK 1743881

Share price
$77.36Close, Nov 16
Market cap
$15.1B
Shares outstanding
194.8MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All BridgeBio Pharma, Inc. filings on SEC EDGAR ↗

4:52 PM ET 10-Q
Financial Results ▶ Call

BridgeBio Pharma Q3 2026 Results: Net Loss of $56.7M, Loss Narrows

BridgeBio Pharma reported a significant increase in total revenues to $791.4 million for the first nine months of 2026, driven primarily by net product revenue from Attruby and Beyonttra. Despite the revenue growth, the company maintained a net loss of $382.9 million due to high research and development and selling expenses, though this was an improvement from the $538.3 million loss in the prior year period.

Key figure
Net loss $56.7M
4:03 PM ET 8-K
Financial Results

BridgeBio Pharma Financial Results

BridgeBio Pharma reported Q3 2026 financial results, highlighted by $353.2 million in total revenue, including $253.2 million from U.S. Attruby net product sales. The company is preparing for three potential product launches in 2026 and 2027 for BBP-418, oral infigratinib, and encaleret, all of which have been granted Priority Review by the FDA.

Term
Q3 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.